Alliances
The University of Chicago’s Polsky Center is designed to set business students who have a mind to become entrepreneurs with scientists hoping to turn their research into a beneficial product.
Shares of Cara Therapeutics are soaring this morning after the company announced it secured $70 million in cash as part of a licensing agreement with Vifor Fresenius Medical Care Renal Pharma Ltd. (VFMCRP) for the company’s chronic kidney disease treatment Korsuva.
Allergan has exercised an option to acquire an oral small molecule compound from Illinois-based Aptinyx, a spinout of Naurex, Inc., which the Irish company acquired in 2015. The company will use it as a complement to a Phase III depression treatment.
Celgene Corporation and Evotec AG announced they have inked a long-term strategic partnership to find and develop new cancer drugs.The partnership will lean on Evotec’s preclinical discovery and development platforms.
Nabriva Therapeutics reported positive topline results from its Phase III clinical trial of oral lefamulin compared to oral moxifloxacin in adults with moderate community-acquired bacterial pneumonia (CABP).
As another HIV Vaccine Awareness Day slides by on the calendar, there is still no cure for the disease. However, many pharma and biotech companies are desperately working on developing therapeutics for the devastating disease.
Danish company Novo Nordisk is a leader in diabetes treatment, but this week announced it was upping its commitment to stem-cell-based therapies and expanding its focus.
Emulate, Inc. struck a deal with pharma giant AstraZeneca’s Innovative Medicines and Early Development (IMED) Biotech Unit to embed its Organs-on-Chips technology within the laboratories of the IMED Drug Safety organization.
There are a few upcoming approval dates for several companies this week. Let’s take a look at the companies and their products awaiting approval.
Beam Therapeutics, a new precision genetic medicines company, launched this morning with $87 million in a Series A funding round backed by F-Prime Capital Partners and ARCH Venture Partners.
PRESS RELEASES